TARA Stock Price | Protara Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Protara Therapeutics Inc • TARA

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Protara Therapeutics Inc

Ticker

TARA

Trading on

NASDAQ

ISIN

US74365U1079

Industry

Biotechnology

Sector

Healthcare

CEO

Jesse Shefferman

Headquarters

345 Park Avenue South, New York, NY, United States, 10010

Employees

Website

protaratx.com

Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations. It is also developing intravenous choline chloride, an investigational phospholipid substrate replacement therapy for patients receiving parenteral nutrition and fluids. The company is headquartered in New York, New York.

Metrics

BasicAdvanced

Market cap

$111M

P/E ratio

EPS

-$1.49

Dividend Yield

0.00%

Beta

1.36

Forward P/E ratio

EBIDTA

$-51.1M

Ex dividend date

Price & volume

Market cap

$111M

Average daily volume

0.3M

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

PEG ratio

Trailing P/E

Price to sales

Price to book

0.74

Earnings

EPS

-$1.49

EPS estimate (current quarter)

-$0.48

EPS estimate (next quarter)

-$0.51

EBITDA

$-51.1M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

1.36

52-week High

$6.88

52-week Low

$1.60

50-day moving average

$3.42

200-day moving average

$3.55

Short ratio

6.81

Short %

5.80%

Management effectiveness

ROE (TTM)

-41.88%

ROA (TTM)

-27.16%

Profit margin

0.00%

Gross profit margin

$0M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

38.6M

Float

34.2M

Insiders %

3.61%

Institutions %

76.24%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 7 analysts.

Average price target

$22.17

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.45

-$0.80

43.75%

Q2 • 24Beat

-$0.50

-$0.52

3.38%

Q3 • 24Beat

-$0.43

-$0.57

23.89%

Q4 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-12.8M

-∞%

Q4 • 24

$0M

$-11.9M

-∞%

Q1 • 25

NaN%

-6.70%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$181M

$14.3M

7.89%

Q4 • 24

$169M

$10.1M

5.98%

Q1 • 25

-7.11%

-29.64%

-24.26%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-9.3M

$22.5M

$97.8M

$-9.3M

Q4 • 24

$-14.7M

$-58.4M

$1.7M

$-14.8M

Q1 • 25

58.07%

-359.35%

-98.23%

58.54%

QoQ growth

QuarterlyAnnual

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Protara Therapeutics Inc share?

Protara Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Protara Therapeutics Inc have?

Protara Therapeutics Inc currently has 38.6M shares.

Does Protara Therapeutics Inc pay dividends?

No, Protara Therapeutics Inc doesn't pay dividends.

What is Protara Therapeutics Inc 52 week high?

Protara Therapeutics Inc 52 week high is $6.88.

What is Protara Therapeutics Inc 52 week low?

Protara Therapeutics Inc 52 week low is $1.60.

What is the 200-day moving average of Protara Therapeutics Inc?

Protara Therapeutics Inc 200-day moving average is $3.55.

Who is Protara Therapeutics Inc CEO?

The CEO of Protara Therapeutics Inc is Jesse Shefferman.

How many employees Protara Therapeutics Inc has?

Protara Therapeutics Inc has 28 employees.

What is the market cap of Protara Therapeutics Inc?

The market cap of Protara Therapeutics Inc is $111M.

What is the P/E of Protara Therapeutics Inc?

The current P/E of Protara Therapeutics Inc is null.

What is the EPS of Protara Therapeutics Inc?

The EPS of Protara Therapeutics Inc is -$1.49.

What is the PEG Ratio of Protara Therapeutics Inc?

The PEG Ratio of Protara Therapeutics Inc is null.

What do analysts say about Protara Therapeutics Inc?

According to the analysts Protara Therapeutics Inc is considered a buy.